Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on X:
“From EGFR to ALK to RET, adjuvant therapy in lung cancer is evolving fast.
ADAURA, ALINA, and LIBRETTO-432 are redefining what ‘curative intent’ can look like after surgery. The question is no longer if we should treat, but who, when, and how long.”
Two Phase 3 Trials That Changed Lung Cancer Treatment in 2025
